Drug Discovery World

MAY 16, 2023

What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? They note that the gene therapy market in general, and the lentiviruses market by association, is growing enormously. DDW’s Megan Thomas finds out.

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

BioPharma Reporter

JULY 5, 2021

Sartorius is strengthening its product portfolio for cell and gene therapies with the acquisition of a majority stake in German reagent manufacturer CellGenix.

Reagent 90

Reagent Gene Therapy Gene Manufacturing 90

BioPharma Reporter

JUNE 29, 2021

The New York based company said the deal will expand its in vitro diagnostic, cell and gene therapy support capabilities.

Reagent 52

Reagent In-Vitro Gene Therapy Gene 52

Roots Analysis

APRIL 5, 2023

In fact, non-viral vectors are significantly less expensive than their virus-based counterparts, implying the potential for use in the development of more affordable gene therapies. Currently, highest number of patent for non-viral transfection reagents and systems is filed in North America region.

Reagent 52

Reagent Marketing Gene Therapy Gene 52

Drug Discovery World

AUGUST 11, 2023

The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients. News round-up for by DDW Digital Content Editor Diana Spencer.

Gene Therapy 52

Gene Therapy Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

SEPTEMBER 25, 2023

CRISPR gene editing companies Integrated DNA Technologies (IDT) and Aldevron have inked a new global distribution agreement to expand CRISPR products for cell and gene therapy customers.

Genome 52

Genome Genomics Gene Editing Medicine 52

BioTech 365

SEPTEMBER 2, 2020

Ready-to-use kit enables rapid adeno-associated virus (AAV) titer determinations during the manufacture of AAV vectors UPPSALA, Sweden–(BUSINESS WIRE)–Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction … Continue (..)

Protein 52

Protein Gene Therapy Reagent Gene 52

Roots Analysis

JUNE 1, 2022

Recent technological advancements have led to development of novel DNA cloning kits and reagents, which are cost-effective, faster and more efficient than conventional methods. DNA Cloning Reagent Providers – Current Market Landscape. DNA Cloning Reagents Market. DNA Cloning Kit Providers – Current Market Landscape.

DNA 52

DNA Genetics Reagent Marketing 52

FDA Law Blog

JANUARY 4, 2023

The next town hall will focus on the clinical development of gene therapy products for rare diseases in February 2023. The Agency referred to its 2011 FDA Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products during the town hall. Common CMC Issues for Phase 1 IND Study.

Reagent 59

Reagent Manufacturing Production Gene Therapy 59

Drug Discovery World

JANUARY 30, 2024

Viral vector manufacturing At the Advanced Therapies Awards ceremony, Dr Luigi Naldini, Director of the San Raffaele Telethon Institute for Gene Therapy, was awarded a Lifetime Achievement Award in recognition of ‘extraordinary contributions to gene therapy’, a field he has helped shape through his pioneering work on lentiviral vectors.

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

Drug Discovery World

MARCH 27, 2023

Download this new white paper ‘Diving deep into cell therapy: An industry perspective’ to find out more. The post New whitepaper: Take a deep dive into cell therapy appeared first on Drug Discovery World (DDW).

Reagent 52

Reagent Manufacturing Development Research 52

Drug Discovery World

MARCH 27, 2023

Cell therapy research has never been more exciting with all of the research ongoing.

Reagent 52

Reagent Manufacturing Development Drugs 52

The Pharma Data

MAY 17, 2021

Academic centers should establish risk management programs to successfully commercialize cell and gene therapy products and to be a viable partner with contract research organizations (CROs) and manufacturers in developing these therapies. . Posted 17 May 2021 | By Joanne S. Eglovitch . Historical origins. .

Development 52

Development Gene Therapy Manufacturing Gene 52

Drug Discovery World

APRIL 3, 2023

As the industry’s awareness of alternatives to traditional antibodies continues to grow, there is increasing demand for these alternatives, which we are seeing particularly within the therapeutic sector, to enable targeted therapeutics and enable the emerging gene therapy market. DS: The company now has clients across big pharma.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Roots Analysis

FEBRUARY 21, 2022

Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production. As a result, NGS library preparation kits have emerged as an innovative technology to overcome the challenges associated with conventional library preparation protocols.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

pharmaphorum

DECEMBER 16, 2022

Maishman brings a wealth of experience to the cell and gene therapy-focused company, having worked at GlaxoSmithKline, Pfizer, Valneva, Alexion, and Recipharm in various leadership roles. Pete previously worked with Amazon, Babylon Health, and Sony. Other pharma supplier hires.

Behavioural Health 52

Behavioural Health Reagent Gene Therapy Production 52

Drug Discovery World

MARCH 13, 2023

The cell and gene therapy (CGT) landscape has grown significantly in the past year. Between the 24 therapies already approved by the FDA 1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. link] “COVID-19 and cell and gene therapy: How to keep innovation on track.”

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52

Roots Analysis

FEBRUARY 23, 2022

In the past two years, close to 3,220 patents related to NGS library preparation kits and reagents have been filed / granted, indicating the heightened pace of innovation. Next Generation Sequencing (NGS) Library Preparation Kits. Strong Intellectual Property Portfolio. Next Generation Sequencing (NGS) Library Preparation Kits.

Genetics 52

Genetics DNA RNA Reagent 52

The Pharma Data

OCTOBER 14, 2020

Bio-Techne’s Woburn facility produces Cloudz Cell Activation Kits, a magnetic-free bead-based technology for the robust and reliable expansion of immune cells, including T cells and NK cells, representing a pivotal component of the cell and gene therapy workflow. ” About Bio-Techne Corporation (NASDAQ: TECH).

Manufacturing 40

Manufacturing Reagent Gene Therapy Protein 40

Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Drug Discovery World

DECEMBER 23, 2022

GenScript USA has expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies. . The 400,000 square-foot cGMP facility enables gene and cell therapy R&D programmes to advance IND filings and clinical trials.

Gene Therapy 52

Gene Therapy Gene Reagent Clinical Trials 52

Drug Discovery World

SEPTEMBER 28, 2022

To further streamline the customer experience, optimised reagent kits with validated antibodies from PerkinElmer’s BioLegend business are also part of the solution. . The post Cell analysis system could streamline cell and gene therapy manufacturing appeared first on Drug Discovery World (DDW). ” . .

Gene Therapy 52

Gene Therapy Manufacturing Gene Reagent 52

Drug Discovery World

OCTOBER 13, 2022

There was a selection of the technologies we will present including cell-based assays, ion indicator dyes, inhibitors, pharmacokinetic assays, bioisimilars, assay development antibodies, conjugation particles and other reagents for your drug discovery and development pipeline. .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

Drug Discovery World

JANUARY 19, 2023

This paid-for advertorial by Catalent appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 One significant challenge in the manufacturing of cell and gene therapies is the production of high-quality plasmid DNA (pDNA). Figure 1: The integrated development pathway for cell and gene therapies.

DNA 52

DNA Manufacturing Gene Therapy Gene 52

Drug Discovery World

FEBRUARY 8, 2023

Svea Cheeseman , Refeyn, explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies. Adeno-associated viruses (AAVs) are a promising, widely used vector for delivering gene therapies. Data were provided by the Cell and Gene Therapy Catapult (London, UK).

Gene Therapy 52

Gene Therapy Gene Antibody Production 52

Drug Discovery World

OCTOBER 12, 2022

Furthermore, the sensitivity of the fluorescent label was shown to be around x100 greater than 2-aminobenzamide, a reagent that has been used extensively in the past to label glycans. . Agilent’s next round of collaboration will look at cell and gene therapy glycan applications. The glycan database . References .

Protein 52

Protein Gene Therapy Antibody Production 52

Drug Discovery World

JUNE 14, 2023

In addition to the collection, processing and storing of adult blood projects, BCA is also involved in providing umbilical cord blood and other tissue products as critical components of cell therapies. One example we are following with anticipation are the two FDA approvals for the first gene therapies for sickle cell disease.

Manufacturing 52

Manufacturing Production Gene Therapy Development 52

Drug Discovery World

DECEMBER 15, 2022

Improve delivery: Clinical translation of gene therapy is dependent on the efficient and safe delivery of gene editing tools into cells, and this can occur either ex vivo or in vivo. In one example, Choi et al.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Nucleic acid-based diagnostics, which typically require PCR reagents and laboratory equipment, are crucial for identifying, treating, and preventing common infectious diseases.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

FEBRUARY 27, 2023

By focusing on workflow simplification and expanded assay capabilities in a state-of-the-art microplate reader, complemented by our optimised reagent technologies, our team has created an all-around high-performing system built for today and the future.”

Drugs 52

Drugs Life Science Protein Scientist 52